Hif-2Α mutated cancers

Clinical trials for Hif-2Α mutated cancers explained in plain language.

Never miss a new study

Get alerted when new Hif-2Α mutated cancers trials appear

Sign up with your email to follow new studies for Hif-2Α mutated cancers, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New pill shows promise for rare tumors in Mid-Stage trial

Disease control Recruiting now

This phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …

Matched conditions: HIF-2Α MUTATED CANCERS

Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control

Last updated Sep 05, 2026 00:00 UTC

Hif-2Α mutated cancers

Get alerted when new Hif-2Α mutated cancers trials appear

New pill shows promise for rare tumors in Mid-Stage trial